Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

A policy approach to the development of molecular diagnostic tests

Nature Biotechnology volume 28, pages 1157–1159 (2010)Cite this article

Subjects

Efficiently generating evidence of clinical utility is a major challenge for ensuring clinical adoption of valuable diagnostics. A new approach to reimbursement in the United States offers a balance between evidence and incentives for molecular diagnostic tests.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. 42 U.S.C. § 1395y(a)(1)(A).

  2. Tunis, S.R. N. Engl. J. Med. 350, 2196–2198 (2004).

    Article  CAS  Google Scholar 

  3. Potti, A. et al. N. Engl. J. Med. 355, 570–580 (2006).

    Article  CAS  Google Scholar 

  4. Acharya, C.R. et al. J. Am. Med. Assoc. 299, 1574–1587 (2008).

    Article  CAS  Google Scholar 

  5. Paik, S. et al. J. Clin. Oncol. 24, 3726–3734 (2006).

    Article  CAS  Google Scholar 

  6. Evans, W.E. & McLeod, H.L. N. Engl. J. Med. 348, 538–549 (2003).

    Article  CAS  Google Scholar 

  7. Bild, A.H. et al. Nature 439, 353–357 (2006).

    Article  CAS  Google Scholar 

  8. Rieder, M.J. et al. N. Engl. J. Med. 352, 2285–2293 (2005).

    Article  CAS  Google Scholar 

  9. Liu, R. et al. N. Engl. J. Med. 356, 217–226 (2007).

    Article  CAS  Google Scholar 

  10. Glickman, S.W. et al. N. Engl. J. Med. 360, 816–823 (2009).

    Article  CAS  Google Scholar 

  11. Modan, B. et al. N. Engl. J. Med. 345, 235–240 (2001).

    Article  CAS  Google Scholar 

  12. Anonymous. (USDHHS, CMS, Baltimore, MD, USA) <https://www.cms.hhs.gov/mcd/ncpc_view_document.asp?id=8> (Accessed May 14, 2008).

  13. Kolata, G. Medicare covering new treatments, but with a catch. New York Times (5 November, 2004).

  14. Tunis, S.R. & Pearson, S.D. Health Aff. 25, 1218–1230 (2006).

    Article  Google Scholar 

  15. Reed, S.D., Shea, A.M. & Schulman, K.A. J. Gen. Intern. Med. 23 Suppl 1, 50–56 (2008).

    Article  Google Scholar 

  16. Ackerly, D.C., Valverde, A.M., Diener, L.W., Dossary, K.L. & Schulman, K.A. Health Aff. 28, w68–w75 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kevin A. Schulman is at the Duke Clinical Research Institute, Duke University School of Medicine and the Health Sector Management Program, The Fuqua School of Business, Duke University, Durham, North Carolina, USA.,

    Kevin A Schulman

  2. Sean R. Tunis is at the Center for Medical Technology Policy, Baltimore, Maryland, USA.,

    Sean R Tunis

Authors
  1. Kevin A Schulman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sean R Tunis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin A Schulman.

Ethics declarations

Competing interests

K.A.S. received research support from Actelion Pharmaceuticals, Allergan, Amgen, Astellas Pharma, Bristol-Myers Squibb, The Duke Endowment, Genentech, Inspire Pharmaceuticals, Johnson & Johnson, Kureha Corporation, LifeMasters Supported SelfCare, Medtronic, Merck & Co., Nabi Biopharmaceuticals, National Patient Advocate Foundation, North Carolina Biotechnology Center, NovaCardia, Novartis, OSI Eyetech, Pfizer, Sanofi-aventis, Scios, Tengion, Theravance, Thomson Healthcare and Vertex Pharmaceuticals; personal income for consulting from McKinsey & Company and the National Pharmaceutical Council; had equity in Alnylam Pharmaceuticals; had equity in and served on the board of directors of Cancer Consultants, Inc; and had equity in and serving on the executive board of Faculty Connection. K.A.S. has made available online a detailed listing of financial disclosures (http://www.dcri.duke.edu/research/coi.jsp). S.R.T. is an employee of the Center for Medical Technology Policy (CMPT), a nonprofit policy and research center that works on issues of comparative effectiveness research and coverage with evidence development. CMPT receives funding from a range of health plans, life sciences companies, foundations and government grants.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schulman, K., Tunis, S. A policy approach to the development of molecular diagnostic tests. Nat Biotechnol 28, 1157–1159 (2010). https://doi.org/10.1038/nbt1110-1157

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1110-1157

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research